Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. Simon, M.; Bosset, P. O.; Rouanne, M.; Benhamou, S.; Radulescu, C.; Molinie, V.; Neuzillet, Y.; Paoletti, X.; Lebret, T.. PLoS One. 2019; 14: p.e0211721. doi:10.1371/journal.pone.0211721Article